Form D · Biotechnology

ADAPTIN BIO, INC.

Charlotte, NC · CIK 0001938571

Offering snapshot reported Jun 22, 2026 · SEC filing

Reported sold
$1.91M
Offering amount: $4M
Investors reported
19
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 22, 2025
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$956K$1.91MJan 5, 2026: $1,000,000.00Jan 5, 2026Feb 20, 2026: $1,297,000.00Feb 20, 2026Mar 23, 2026: $1,652,000.00Mar 23, 2026Jun 22, 2026: $1,912,000.00Jun 22, 2026

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$1,652,000 → $1,912,000
  • Reported investors13 → 19

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 22, 2026Amendment$1,912,000$260,000vs Mar 23, 202619SEC filing
Mar 23, 2026Amendment$1,652,000$355,000vs Feb 20, 202613SEC filing
Feb 20, 2026Amendment$1,297,000$297,000vs Jan 5, 202610SEC filing
Jan 5, 2026Initial$1,000,000No comparison7SEC filing
Feb 26, 2025Initial$13,077,849No comparison95SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$229K (estimated)
Finders' fees
$0
Form D file number
021-568890
Based on total amount sold as of date of first sale. In addition to the sales commissions, warrants to purchase up to an aggregate of 80,000 shares of our common stock will be issued to the placement agent at the final closing.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Laidlaw & Company (UK) Ltd.119037

Source: Form D, filed Jun 22, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Patrick Gallagher Director
L. Arthur Hewitt Executive
Timothy Maness Executive
Simon Pedder Director, Executive
J. Nick Riehle Director
Michael Roberts Director, Executive
Anthony Zook Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
3540 Toringdon Way Suite 200, #250
Charlotte, NC, 28277